Drug trials: what value should pharma firms assign to rivals’ success?
Drug companies pay close attention to early-stage investment and testing by rivals, but only successful demonstrations of clinical proof of concept really matter, says new study co-authored at Cambridge Judge Business School. As in all competitive industries, pharmaceutical companies carefully…
Venturing forth: Qureight – integrating data with AI to solve complex diseases
Qureight, a clinical data analytics company supported by the Accelerate Cambridge programme at Cambridge Judge Business School, just raised £1.5m in seed funding. Qureight, a clinical data analytics firm supported by Cambridge Judge Business School, had its origins in a…
India Education Diary: New book highlights how small biotech companies are outperforming big pharma
From Breakthrough to Blockbuster: The Business of Biotechnology, a new book co-authored by Nektarios Oraiopoulos, Associate Professor at Cambridge Judge Business School, shows how small, inexperienced entrepreneurial companies making up the biotech industry have created more life-changing medicines than all…
Carryover co-operation
Sir Mene Pangalos of AstraZeneca, in a Cambridge Judge interview, urges continuation of the 'exceptional' collaboration between industry, academia, government and regulators that led to rapid development of COVID-19 vaccines. Sir Mene Pangalos The "exceptional" collaboration between the pharmaceutical industry,…
Biopharm expansion
Apollo Therapeutics, a life sciences company led by Cambridge Judge Business School alumnus and Fellow Dr Richard Mason, completes $145 million financing. Apollo Therapeutics, a biopharmaceutical company headed by Cambridge Judge Business School MBA alumnus and Fellow Dr Richard Mason…
United Press International: Study: Second opinion can reduce risk for long-term opioid use
A study looking at opioid use co-authored by Stefan Scholtes, Dennis Gillings Professor of Health Management at Cambridge Judge Business School, featured in United Press International. The study found that “a “second opinion” by another prescribing doctor within 30 days…
Opioid intervention
'Second opinion' by another prescribing doctor within 30 days of an opioid prescription reduces long-term opioid use by 31%, concludes a new study led at Cambridge Judge Business School. A "second opinion" by another prescribing doctor within 30 days of…
Stock sales
Three US senators cite research by Professor Alan Jagolinzer of Cambridge Judge Business School in urging SEC reform of insider trading laws. Professor Alan Jagolinzer Three US senators cited research co-authored by Professor Alan Jagolinzer of Cambridge Judge Business School in urging the Securities…
Good reporting
Annual reports should inform society – not just shareholders – about vital issues such as the financial health and environmental impact of organisations, says Professor Alan Jagolinzer of Cambridge Judge Business School. Professor Alan Jagolinzer By Professor Alan Jagolinzer Corporate…
Forbes India: How drug companies can increase their R&D effectiveness
A study co-authored by Professor Stylianos Kavadias and Dr Nektarios Oraiopoulos at University of Cambridge Judge Business School, is featured in the Forbes article. The study demonstrates “how pharmaceutical executives can impact the success of their research and development” programs…